Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Carfilzomib in combination with Thalidomide and Dexamethasone for remission induction and consolidation of Multiple Myeloma at first presentation

Next Previous
Trial Profile

Carfilzomib in combination with Thalidomide and Dexamethasone for remission induction and consolidation of Multiple Myeloma at first presentation

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 01 Aug 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carfilzomib (Primary) ; Dexamethasone; Melphalan; Thalidomide
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms CARTHADEX
  • Sponsors Erasmus MC; Onyx Pharmaceuticals

Most Recent Events

  • 17 Jun 2018 Results presented at the 23rd Congress of the European Haematology Association
  • 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
  • 06 Dec 2016 Results of 4 dose levels presented at the 58th Annual Meeting and Exposition of the American Society of Hematology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top